> Support continues for extending hormonal therapy in early-stage hormone receptor-positive breast cancers

Support continues for extending hormonal therapy in early-stage hormone receptor-positive breast cancers

general_content

Findings announced at the San Antonio Breast Cancer Symposium offer more evidence that continuing hormonal therapy after five years prevents recurrences.

Thursday morning’s presentations at the 2018 San Antonio Breast Cancer Symposium focused on treatments for hormone receptor-positive breast cancers. Three studies looked at how hormonal therapy is given, focusing on how long people with early-stage disease should take hormonal therapy and at what dose. The SOLAR-1 trial looked at a new targeted therapy for people with metastatic breast cancer whose disease has a mutation in the PI3K pathway, which occur in 40 percent of hormone receptor-positive breast cancers.

about_this_page_tabbed_module
About this page
Glossary
About LBBC

Eric Fitzsimmons

Eric Fitzsimmons headshot
  • Former LBBC staff writer and content coordinator

Tagged:

Was this page helpful?

Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.